Global Medicinal Cannabis Market Size By Type (Oral Medications, Topical Medications), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Medicinal Cannabis Market was valued at USD 19.2 billion in 2023 and is expected to reach USD 56.8 billion by 2031, growing at a CAGR of 14.5% during the forecast period from 2023 to 2031. The market's rapid growth is primarily attributed to increasing recognition of cannabis as a therapeutic alternative for a wide range of conditions, including chronic pain, epilepsy, multiple sclerosis, and chemotherapy-induced nausea. Legislative reforms in various countries and increasing investment in research and development are further supporting the mainstream acceptance of medicinal cannabis.

Drivers

1. Expanding Legalization of Medicinal Cannabis

Ongoing regulatory reforms across North America, Europe, and parts of Asia-Pacific are enabling broader access to medicinal cannabis, driving its demand across both emerging and developed markets.

2. Rising Burden of Chronic Diseases

The global increase in chronic diseases such as cancer, arthritis, and neurological disorders is prompting healthcare providers to consider cannabis-based therapies as adjunct treatments due to their effectiveness and safety profile.

3. Growing R&D and Clinical Trials

Major pharmaceutical and biotech firms are ramping up investments in clinical research to explore the efficacy of cannabinoids in treating conditions such as PTSD, sleep disorders, and anxiety, creating new opportunities for growth.

Restraints

1. Regulatory Inconsistencies

Despite a general trend toward legalization, significant differences in cannabis regulations between countries and even within regions pose a challenge for international trade and investment.

2. Limited Clinical Evidence

The lack of large-scale, long-term clinical studies on cannabis' efficacy and safety continues to impede its widespread medical adoption, especially in conservative medical markets.

Opportunity

1. Emergence of New Delivery Systems

The development of novel delivery methods—such as transdermal patches, sublingual sprays, and edibles—offers convenience and improved dosage accuracy, attracting both physicians and patients.

2. Expansion into Untapped Markets

Regions such as Latin America, Southeast Asia, and parts of Eastern Europe represent significant growth potential as governments begin to loosen restrictions on medicinal cannabis use.

Market by System Type Insights

Based on product type, the Cannabidiol (CBD) Oil segment held the largest share in 2023 due to its non-psychoactive properties and versatility in treating various medical conditions. However, the Tetrahydrocannabinol (THC)-dominant segment is projected to witness the fastest growth owing to its proven effectiveness in pain management and appetite stimulation in cancer and HIV/AIDS patients.

Market by End-use Insights

By end-use, the Pharmaceuticals segment dominated the market in 2023, accounting for over 40% of total revenue. This segment benefits from increasing prescription rates, strong product pipelines, and high R&D activity. The Wellness and Personal Care segment is also experiencing significant momentum, driven by rising consumer interest in cannabis-infused skincare, supplements, and health products.

Market by Regional Insights

North America led the global medicinal cannabis market in 2023, bolstered by strong consumer demand, favorable regulatory frameworks in the U.S. and Canada, and a robust research infrastructure. Europe is emerging as a key growth region, with countries such as Germany, the UK, and Italy gradually expanding access. Meanwhile, the Asia-Pacific region is expected to register the fastest growth during the forecast period due to rising healthcare investments and evolving attitudes toward cannabis-based therapies.

Competitive Scenario

Key players in the Global Medicinal Cannabis Market include Aurora Cannabis Inc., Canopy Growth Corporation, Tilray Brands Inc., GW Pharmaceuticals (a Jazz Pharmaceuticals company), Cronos Group, Curaleaf Holdings Inc., Trulieve Cannabis Corp., Green Thumb Industries, HEXO Corp., and Medical Marijuana Inc. These companies are actively involved in new product launches, clinical research, geographic expansion, and strategic collaborations to strengthen their market presence.

Scope of Work – Global Medicinal Cannabis Market

Key Market Developments

2023: GW Pharmaceuticals initiated Phase III clinical trials for a THC/CBD combination drug targeting multiple sclerosis spasticity.

2024: Canopy Growth partnered with a European pharmaceutical distributor to expand access to its cannabis-based medicines across the EU.

2025: Tilray acquired a U.S.-based CBD wellness brand to enter the high-growth personal care segment in North America.

FAQs

1) What is the current market size of the Global Medicinal Cannabis Market?

The market was valued at USD 19.2 billion in 2023.

2) What is the major growth driver of the Global Medicinal Cannabis Market?

The primary growth driver is the global trend toward legalization and increasing use of cannabis in managing chronic conditions.

3) Which is the largest region during the forecast period in the Global Medicinal Cannabis Market?

North America is the largest and most mature market for medicinal cannabis.

4) Which segment accounted for the largest market share in the Global Medicinal Cannabis Market?

The CBD Oil segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Medicinal Cannabis Market?

Key players include Aurora Cannabis, Canopy Growth, Tilray, GW Pharmaceuticals, Cronos Group, and Curaleaf Holdings.